Pretreatment physical function as a risk factor for movement and neurocognitive treatment-emergent events (MNTs) in multiple myeloma (MM) patients treated with cilta-cel
Authors:
- 26 January 2026
- journal article
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 482, 125771
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health National Cancer Institute (P30CA016056)
This publication has 6 references indexed in Scilit:
- Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatmentBlood, 2025
- Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpJournal of Clinical Oncology, 2023
- Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studiesBlood Cancer Journal, 2022
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyThe Lancet, 2021
- Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell-Associated Encephalopathy (ICE) ScoreTransplantation and Cellular Therapy, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019